#Ireland #Dublin #Nuritas #Kees Kruythoff #bioactive peptides

Kees Kruythoff Appointed as Board Chair at Nuritas

In a significant move for the biotech industry, Nuritas has announced the appointment of Kees Kruythoff as the new Chair of its Board of Directors. Formerly the president of Unilever North America, Kruythoff brings with him nearly 30 years of rich experience in global leadership roles across various markets.

Kruythoff's journey at Unilever saw him spearheading lucrative businesses with revenues spanning from €200 million to €12 billion. His most notable roles included serving as the president of Unilever North America and overseeing the global Home Care division. He has had operational oversight in diverse regions such as Europe, Africa, Asia, and Latin America, making him well-versed in scaling innovations through global consumer brands and commercial alliances.

Nuritas, renowned for its pioneering approach in discovering bioactive peptides, aims to revolutionize the food industry by transforming everyday food into clinically-proven healthier ingredients. The company utilizes its proprietary discovery platform, Magnifier NπΦ, to analyze natural proteins, unearthing impactful peptides aimed at addressing critical human health needs.

Kruythoff expressed enthusiasm about the opportunity at Nuritas: "I believe Nuritas has a unique chance to greatly influence the health and wellbeing of billions by combining natural ingredients with cutting-edge AI technology for peptide discovery. I am honored and excited to be part of this journey.”

Dr. Nora Khaldi, the founder and CEO of Nuritas, emphasized the importance of Kruythoff’s appointment, stating, "Kees brings global scale, operational discipline, and a genuine passion for food transformation to our board. His expertise in market development and integrating health and sustainability in global consumer businesses makes him the ideal partner for Nuritas at this crucial juncture. We are thrilled to welcome him aboard.”

Working closely with Khaldi and the executive team, Kruythoff will provide strategic guidance as Nuritas deepens its relationships with global partners and expands the commercial reach of its peptide portfolio. This move reinforces the company's position at the intersection of artificial intelligence, biotechnology, and human health.

Nuritas stands out in the biotechnology sector as it leverages artificial intelligence to discover clinically validated natural peptides. Its Magnifier NπΦ platform enables swift analysis of proteins, identifying peptides that hold promise for boosting human health, allowing their partners to bring scientifically-backed innovations to market faster.

Established in 2014 by mathematician and scientist Dr. Nora Khaldi, Nuritas is headquartered in Dublin, Ireland, with its North American office located in Connecticut. The company collaborates with major partners, including GNC, The Vitamin Shoppe, Mars, Nestlé, and Givaudan, showcasing its credibility and ambition to lead in the health and nutrition landscape.

As Nuritas embarks on this new chapter with Kees Kruythoff at the helm of the Board, the future seems bright for innovations that will not only enhance the nutrition of everyday foods but also significantly improve human health on a global scale. The combination of Kruythoff’s expansive experience and Nuritas’ innovative approach promises to yield substantial advancements in the food science arena.